Description Tirzepatide: Complete Research Guide Dual GIP/GLP-1 Receptor Agonist Mechanisms, Clinical Evidence, and Metabolic Research Last updated: March 2026 Executive Summary Tirzepatide is a first-in-class dual glucose-dependent insulinotropic polypeptide (GIP) and glucagon-like peptide-1 (GLP-1) receptor agonist developed by Eli Lilly and Company
More serious side effects to be aware of include: Severe, persistent abdominal pain (with or without vomiting) seek urgent medical care as this could indicate acute pancreatitis Upper right abdominal pain or jaundice may indicate gallbladder disease Risk of dehydration maintain adequate fluid intake to reduce risk of acute kidney injury Potential worsening of diabetic retinopathy in those with pre-existing condition Increased risk of hypoglycaemia when used with insulin or sulfonylureas (dose adjustments may be needed) Patients should inform surgical and anaesthetic teams about tirzepatide use due to its effect on gastric emptying, which may increase aspiration risk during procedures
Research indicates that participants in structured programs report an average body weight loss of 15% after 68 weeks, with some achieving losses exceeding 20-25% within a year
These hormones help regulate blood sugar, appetite, and how the body stores and burns fat
In clinical trials, it has shown effectiveness in reducing hemoglobin A1c levels, promoting insulin sensitivity, and assisting with weight loss
